'First of its kind' lung cancer trial
Scientists have been awarded £900,000 from Cancer Research UK to launch a ground-breaking clinical trial for people with lung cancer.
The CONCORDE trial will explore the use of new drugs alongside standard radiotherapy in the hope of improving survival for people with advanced non-small cell lung cancer (NSCLC).
The trial involves research teams from the universities of Leeds, Newcastle, Manchester and Glasgow.
Lung cancer is the third most common cancer in the UK, with about 47,800 people diagnosed each year. Between 80-85% of lung cancers in the UK are NSCL, which start in the mucus-making gland cells in the lining of the airways.
Its smart design means that we can study the benefit of a range of new treatments that target the tumour DNA.